\u201cI’m thrilled to be joined by the leaders of nine of the world’s largest pharmaceuticals … it\u2019s a great group to announce that they’ve agreed to offer many of their flagship drugs, really all of their flagship drugs, at heavily discounted Most Favored Nations prices<\/a>,\u201d Trump<\/a> said Friday. <\/p>\n \u201cThis represents the greatest victory for patient affordability in the history of American health care … this is the biggest thing ever to happen on drug pricing and on health care. This will have a tremendous impact on health care itself.\u201d<\/p>\n According to the White House, the manufacturers who are joining the president\u2019s pricing scheme are Amgen Boringer, Ingelheim, Bristol-Myers-Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi, bringing the total number of drug companies participating to 14. The plan brings down prices for common drugs to more in line with what are paid in other parts of the world. <\/p>\n A senior administration official who briefed reporters ahead of the Friday\u2019s White House announcement said the companies had also agreed to make \u201c$150 billion in combined new investment commitments in manufacturing and research and development here in the United States\u201d in addition to agreeing to lower prices paid by Americans.<\/p>\n The companies will also kick back a portion of foreign revenue to the U.S. as a way to defray costs to American patients. <\/p>\n The official said Medicaid would be the first to benefit from the pricing scheme. Americans will also be able to access the lower-cost prescriptions on the administration\u2019s Trump Rx website, which a White House official said is set to go live for use next month. <\/p>\n open image in gallery<\/p>\n President Donald Trump announced more drug companies signed on to his prescription drug program in his push to lower prices. (Getty Images)<\/p>\n Trump\u2019s \u201cmost favored nation\u201d pricing model is aimed at making medications more affordable for low-income Americans, including those on Medicaid, by way of the yet-to-be-launched website. <\/p>\n \u201cThis is what bold leadership delivers. Where others have talked President Trump is acting, and where the establishment, including industry, said it couldn’t be done, the President has proved them wrong, and the days of American families subsidizing cut rate drugs for the rest of the world are ending,\u201d the official said.<\/p>\n According to the same official, the drug companies\u2019 combined investment into American manufacturing will help the process of \u201crebuilding American pharmaceutical might\u201d and contribute to \u201cmore research on the next generation of live-saving drugs\u201d as well as to \u201cnational security and more American independence.\u201d <\/p>\n He added that \u201cseveral\u201d of the companies will be donating ingredients to the government\u2019s Strategic Active Pharmaceutical Ingredients Reserve.<\/p>\n Merck, for example, will donate a six-month supply of Erdopenem, a \u201cpowerful broad-spectrum antibiotic\u201d indicated for treating \u201cserious infections, including pneumonia, abdominal infections and complicated skin infections … when other common antibiotics fail.\u201d<\/p>\n Bristol Myers Squibb will also contribute a six-month supply of Apixaban, a blood thinner sold under the name Eliquis. And GSK will provide the reserve with a six-month supply of the asthma inhaler medication Albuterol.<\/p>\n \u201cWhat makes this particularly unique is these manufacturers are not only donating this API, they’re also agreeing to convert these raw ingredients into finished medications when needed during emergencies, and to help distribute them to the Americans that need them most,\u201d the official added.<\/p>\n open image in gallery<\/p>\n The companies joining Trump will now offer drugs at the \u2018Most Favored Nations\u2019 prices. (AFP via Getty Images)<\/p>\n Friday\u2019s announcement is the latest in a series of events in which Trump has boasted of securing cooperation from drug makers who traditionally charged lower prices to countries with single-payer health care systems that could use economies of scale to negotiate better wholesale costs. <\/p>\n Last month, the president said GLP-1 makers Eli Lilly and Novo Nordisk were \u201cjoining the phenomenal list\u201d of drug companies that have capitulated to his administration\u2019s demand that they offer their products on a \u201cmost-favored nation\u201d pricing plan, bringing the cost Americans pay for their drugs down to a level on par with countries that pay lower prices through their single-payer health care systems.<\/p>\n For example, Trump said the cost of Wegovy would drop under the plan from $1,350 per month to $250 per month, with Zepbound dropping from $1,080 to $346. Once approved, Eli Lilly\u2019s weight-loss pill will be available for $149.<\/p>\n Earlier this year, Trump announced deals with drug makers Pfizer, AstraZeneca <\/a>and EMD Serono would also make their products available on TrumpRx and invest billions into the U.S. for research and development.<\/p>\n The president first pushed the idea of forcing drug companies<\/a> to match prices offered abroad during his previous term but faced significant resistance from the industry, including pushback in a lawsuit<\/a> that resulted in a federal court order blocking his administration from carrying the plan out because it had failed to follow proper regulatory procedures. <\/p>\n After returning to the White House, he revived the plan in an executive order<\/a> he issued in May which directed his administration to take various actions to bring drug prices in the U.S. in line with prices negotiated between pharmaceutical companies and foreign countries that have single-payer health systems such as the British NHS<\/a>. <\/p>\n![\"President](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2025\/12\/GettyImages-2252755410.jpeg\")
<\/p>\n![\"The](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2025\/12\/GettyImages-2252071179.jpeg\")
<\/p>\n